Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway
about
Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advancesAspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the futureEosinophil production of prostaglandin D2 in patients with aspirin-exacerbated respiratory disease.Exploration of the Sphingolipid Metabolite, Sphingosine-1-phosphate and Sphingosine, as Novel Biomarkers for Aspirin-exacerbated Respiratory Disease.Aspirin Intolerance: Experimental Models for Bed-to-Bench.Cyclooxygenase 2: its regulation, role and impact in airway inflammation.Leukotriene C4 Potentiates IL-33-Induced Group 2 Innate Lymphoid Cell Activation and Lung Inflammation.Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations.Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.Update on Aspirin-Exacerbated Respiratory Disease.Potential Biomarkers for NSAID-Exacerbated Respiratory DiseaseRole of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis.Type 2 Cysteinyl Leukotriene Receptors Drive IL-33-Dependent Type 2 Immunopathology and Aspirin Sensitivity.An update on the management of aspirin-exacerbated respiratory disease.Microparticles in nasal lavage fluids in chronic rhinosinusitis: Potential biomarkers for diagnosis of aspirin-exacerbated respiratory disease.Lysosome biogenesis regulated by the amino-acid transporter SLC15A4 is critical for functional integrity of mast cells.
P2860
Q26750424-97E5EE1F-ED84-4712-84BC-415F19CABE87Q30238776-5FDC809E-9B8D-4D65-A4FC-ACBFE3A1AAB9Q30276354-342B790C-0922-4C94-843F-076687D04FF2Q37405580-E390603F-0E33-43A5-9035-62D84A612228Q37692720-71052654-F628-4647-9999-8C4FCA8EB4ABQ38674101-34DF8576-42F2-41AF-95AF-5DEA5DA4338BQ38699307-C2F9EC3B-427F-456E-B54E-D36285FD50DAQ38915358-A4187DDF-A280-458F-A5B1-F9D50C3D9AEBQ38916857-6F761F3B-2606-4016-A973-14ED7A8A75B3Q39093155-432E0A96-1557-4A59-AFCE-3C0E7E43DD75Q41500425-C8D12B8F-E59C-4B55-AA89-C80A0BF0534AQ47656375-B5014539-7EC8-4816-836A-C5419BD98533Q47669026-E0646783-00C6-4037-8909-1EBEE14EEAA1Q47678797-098FBAEF-994B-4A06-B57A-D88354D9F527Q47964479-C6D0A4F5-1425-46DE-9AB2-4D668F0D5E4CQ54314108-027F66D0-5A0D-4FDB-84F1-FCB3FEBA5A27
P2860
Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Aspirin-Exacerbated Respirator ...... d Mast Cell Activation Pathway
@ast
Aspirin-Exacerbated Respirator ...... d Mast Cell Activation Pathway
@en
type
label
Aspirin-Exacerbated Respirator ...... d Mast Cell Activation Pathway
@ast
Aspirin-Exacerbated Respirator ...... d Mast Cell Activation Pathway
@en
prefLabel
Aspirin-Exacerbated Respirator ...... d Mast Cell Activation Pathway
@ast
Aspirin-Exacerbated Respirator ...... d Mast Cell Activation Pathway
@en
P2093
P2860
P356
P1476
Aspirin-Exacerbated Respirator ...... d Mast Cell Activation Pathway
@en
P2093
Chunli Feng
Denise Garofalo
Howard R Katz
Joshua A Boyce
Juying Lai
Kathleen Buchheit
Neil Bhattacharya
Nora A Barrett
Tanya M Laidlaw
P2860
P304
P356
10.4049/JIMMUNOL.1500905
P407
P577
2015-09-04T00:00:00Z